Article: Targeted Genetics Corporation Announces Strategic Alliance.

- Targeted Genetics to Receive Exclusive Rights to Seminal

AAV Manufacturing Patent from Alkermes, Inc. -

SEATTLE, June 10 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN) today announced an alliance with Alkermes, Inc. (Nasdaq: ALKS) that provides Targeted Genetics with exclusive rights to a seminal patent for the manufacture of Adeno-Associated Viral (AAV) vectors.

Under the terms of the agreement, Targeted Genetics will issue 500,000 shares of common stock as payment for an up-front license fee to Alkermes for exclusive rights to the issued patent and related pending patent applications. In addition, Targeted Genetics will issue to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!